WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328037

CAS#: 116313-94-1

Description: Nitecapone, also known as OR-462, is a catechol-O-methyltransferase inhibitor potentially for the treatment of peptic ulcer. Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats. Nitecapone reduces cardiac neutrophil accumulation in clinical open heart surgery. Nitecapone inhibits myeloperoxidase in vitro and enhances functional performance after 8 h of ischemia in experimental heart transplantation.

Chemical Structure

CAS# 116313-94-1

Theoretical Analysis

MedKoo Cat#: 328037
Name: Nitecapone
CAS#: 116313-94-1
Chemical Formula: C12H11NO6
Exact Mass: 265.0586
Molecular Weight: 265.221
Elemental Analysis: C, 54.34; H, 4.18; N, 5.28; O, 36.19

Price and Availability

Size Price Availability Quantity
5.0mg USD 210.0 2 Weeks
10.0mg USD 360.0 2 Weeks
25.0mg USD 690.0 2 Weeks
Bulk inquiry

Synonym: Nitecapone; OR-462; OR 462; OR462.

IUPAC/Chemical Name: 3-(3,4-Dihydroxy-5-nitrobenzylidene)-2,4-pentanedione


InChi Code: InChI=1S/C12H11NO6/c1-6(14)9(7(2)15)3-8-4-10(13(18)19)12(17)11(16)5-8/h3-5,16-17H,1-2H3

SMILES Code: CC(/C(C(C)=O)=C/C1=CC([N+]([O-])=O)=C(O)C(O)=C1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 265.221 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kambur O, Männistö PT, Pusa AM, Käenmäki M, Kalso EA, Kontinen VK. Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats. Eur J Pain. 2011 Aug;15(7):732-40. doi: 10.1016/j.ejpain.2010.12.001. PubMed PMID: 21216640.

2: Singh A, Kulkarni SK. Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):23-9. PubMed PMID: 11980384.

3: Pertovaara A, Wei H, Kalmari J, Ruotsalainen M. Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp Neurol. 2001 Feb;167(2):425-34. PubMed PMID: 11161631.

4: Vainikka T, Heikkilä L, Toivonen HJ, Rämö J, Hyytinen TA, Mattila SP. The effect of nitecapone on early graft function in experimental single lung transplantation. Scand Cardiovasc J. 2000 Aug;34(4):415-20. PubMed PMID: 10983677.

5: Vento AE, Aittomäki J, Verkkala KA, Heikkilä LJ, Salo JA, Sipponen J, Rämö OJ. Nitecapone as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting. Ann Thorac Surg. 1999 Aug;68(2):413-20. PubMed PMID: 10475405.

6: Pesonen EJ, Vento AE, Rämo J, Vuorte J, Jansson SE, Repo H. Nitecapone reduces cardiac neutrophil accumulation in clinical open heart surgery. Anesthesiology. 1999 Aug;91(2):355-61. PubMed PMID: 10443596.

7: Vento AE, Rämö OJ, Nemlander AT, Ahotupa M, Nissinen E, Holopainen A, Mattila SP. Nitecapone inhibits myeloperoxidase in vitro and enhances functional performance after 8 h of ischemia in experimental heart transplantation. Res Exp Med (Berl). 1999 Apr;198(6):299-306. PubMed PMID: 10369086.

8: Vento AE, Rämö OJ, Pesonen EJ, Heikkilä L, Nissinen E, Holopainen A, Mattila SP. The Effect of Nitecapone, a New Antioxidant, on Myocardial Function After Aortic Cross-clamping in Experimental Heart Ischemia. Int J Angiol. 1999 Jan;8(1):16-21. PubMed PMID: 9826401.

9: Lautala P, Kivimaa M, Salomies H, Elovaara E, Taskinen J. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes. Pharm Res. 1997 Oct;14(10):1444-8. PubMed PMID: 9358559.

10: Vento AE, Rämö OJ, Nemlander AT, Nissinen E, Holopainen A, Mattila SP. Nitecapone is of benefit to functional performance in experimental heart transplantation. Res Exp Med (Berl). 1997;197(3):137-46. PubMed PMID: 9406281.

11: Haramaki N, Stewart DB, Aggarwal S, Kawabata T, Packer L. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Biochem Pharmacol. 1995 Sep 7;50(6):839-43. PubMed PMID: 7575646.

12: Pentikäinen MO, Lindstedt KA, Kovanen PT. Inhibition of the oxidative modification of LDL by nitecapone. Arterioscler Thromb Vasc Biol. 1995 Jun;15(6):740-7. PubMed PMID: 7773727.

13: Nissinen E, Lindén IB, Pohto P. Antioxidant properties of nitecapone are potentiated by glutathione. Biochem Mol Biol Int. 1995 Feb;35(2):387-95. PubMed PMID: 7663394.

14: Marcocci L, Maguire JJ, Packer L. Nitecapone: a nitric oxide radical scavenger. Biochem Mol Biol Int. 1994 Oct;34(3):531-41. PubMed PMID: 7833830.

15: Salmela KS, Roine RP, Höök-Nikanne J, Kosunen TU, Salaspuro M. Effect of bismuth and nitecapone on acetaldehyde production by Helicobacter pylori. Scand J Gastroenterol. 1994 Jun;29(6):528-31. PubMed PMID: 8079111.

16: Wikberg T, Vuorela A. Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile. Eur J Drug Metab Pharmacokinet. 1994 Apr-Jun;19(2):125-35. PubMed PMID: 8001593.

17: Marcocci L, Suzuki YJ, Tsuchiya M, Packer L. Antioxidant activity of nitecapone and its analog OR-1246: effect of structural modification on antioxidant action. Methods Enzymol. 1994;234:526-41. PubMed PMID: 7808329.

18: Tu Y, Ranta S, Nissinen E, Lindén IB. Protection by nitecapone against sodium taurocholate-induced damage to cultured gastric cells. Dig Dis Sci. 1993 Apr;38(4):701-7. PubMed PMID: 7681749.

19: Slomiany BL, Murty VL, Piotrowski J, Morita M, Slomiany A. Glycosulfatase activity of Helicobacter pylori towards gastric sulfomucin: effect of nitecapone. J Physiol Pharmacol. 1993 Mar;44(1):7-16. PubMed PMID: 8518427.

20: Valenza M, Serbinova E, Packer L, Khwaja S, Catudioc J. Nitecapone protects the Langendorff perfused heart against ischemia-reperfusion injury. Biochem Mol Biol Int. 1993 Mar;29(3):443-9. Erratum in: Biochem Mol Biol Int 1993 May;30(1):197. PubMed PMID: 8485462.